Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
CytRx Corporation Common Stock Intraday Chart
|Intraday||Last 52 Weeks|
|High||$ 3.44||$ 5|
|Low||$ 3.10||$ 1.549|
The current last sale of $3.26 is 110.46% Higher thanthe 52 week low.
Company Description (as filed with the SEC)
We are a biopharmaceutical research and development company specializing in oncology. We currently are focused on the clinical development of aldoxorubicin (formerly known as INNO-206), our modified version of the widely-used chemotherapeutic agent, doxorubicin. We have reported positive top-line efficacy results (median progression-free survival, progression-free survival at six months, overall response rates, hazard ratios and overall survival) from our completed, global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, or STS. Hazard ratios - the likelihood that the study endpoint (in this case tumor progression) will be reached during a given period - are an important measure of the reliability and uniformity of the absolute data for progression-free survival, or PFS. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable STS. ... More ...
Where does CYTR fit in the risk graph?
Nasdaq Official Price
|Annual EPS Est:||$-1.02|
|Quarterly EPS Est:||-0.25|